MADISON HEIGHTS, Mich., Oct. 18, 2017 /PRNewswire/ -- InfuSystem Holdings, Inc. (NYSE American: INFU) ("InfuSystem" or the "Company"), a leading provider of oncology infusion pumps and related services in North America, announced a feature segment that recently ran on a leading cable TV channel highlighting how InfuSystem infusion technology improves the quality of life of a patient going through the process of receiving chemotherapy.

Entitled "At-Home Infusion Made Easy," the segment ran on "The Balancing Act" Lifetime TV morning show on October 5th. The segment can be viewed on-demand at www.infusystem.com/LifetimeTV .

Featured in the segment is one of the over 300,000 new patients with gastrointestinal cancers that are estimated by the American Cancer Society to be diagnosed annually in the U.S. InfuSystem treats a large number of these patients with hardware, medication and services that serve as the gold standard in the industry.

"I get to get my chemo on the run... and that makes my life a whole lot easier," said the patient of his InfuSystem experience. As shown in the Lifetime TV segment, InfuSystem patients are able to spend more time in the comfort of their own home while receiving their infusion therapy.

Rich DiIorio, Executive Vice President at InfuSystem, said, "You'll see a great example of how InfuSystem patients are able to receive critically-important treatment in the comfort of their own homes. This allows them to continue to engage in the activities that are important to them, as opposed to spending their time in a hospital or infusion clinic."

"When it comes to immunocompromised chemotherapy patients," Mr. Dilorio continued, "more time in a hospital is generally not a good thing given the risk of hospital-borne infection, the anxiety resulting from being away from home, and the extraordinary costs associated with hospital stays."

"We hope that the Lifetime segment featuring a patient sharing his at-home experience with a broadcast audience will help to empower viewers, some of whom are currently, or at some point in the future will be, diagnosed with a treatable form of cancer, to learn more about their infusion therapy options, and thus make better-informed decisions about their own care and treatment."

The segment aired on Lifetime TV and will continue to air on affiliate stations. The segment may also be viewed on-demand at www.infusystem.com/LifetimeTV .

About InfuSystem Holdings, Inc.

InfuSystem Holdings, Inc. is a leading provider of infusion pumps and related services to hospitals, oncology practices and other alternate site healthcare providers. With headquarters in Madison Heights, Michigan, the Company delivers local, field-based customer support and also operates Centers of Excellence in Michigan, Kansas, California, Texas, Georgia and Ontario, Canada. The Company's stock is traded on the NYSE American under the symbol INFU.

Forward-Looking Statements

Statements made in this press release that are not historical facts are considered to be forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The words "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "should," "plan," "expect," "strategy," "future," "likely," variations of such words, and other similar expressions, as they relate to the Company, are intended to identify forward-looking statements. However, the absence of these words or similar expressions does not mean that a statement is not forward-looking. Forward-looking statements include statements relating to future actions, business plans, objectives and prospects, future operating or financial performance. In connection with the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, the Company is identifying certain factors that could cause actual results to differ, perhaps materially, from those indicated by these forward-looking statements. Those factors, risks and uncertainties include, but are not limited to, potential changes in overall healthcare reimbursement, including CMS competitive bidding, sequestration, concentration of customers, increased focus on early detection of cancer, competitive treatments, dependency on Medicare Supplier Number, availability of chemotherapy drugs, global financial conditions, changes and enforcement of state and federal laws, natural forces, competition, dependency on suppliers, risks in acquisitions & joint ventures, U.S. Healthcare Reform, relationships with healthcare professionals and organizations, technological changes related to infusion therapy, dependency on websites and intellectual property, the ability of the Company to successfully integrate acquired businesses, dependency on key personnel, dependency on banking relations and covenants, and other risks associated with our common stock, as well as any litigation to which the Company may be involved in from time to time; and other risk factors as discussed in the Company's annual report on Form 10-K for the year ended December 31, 2016 and in other filings made by the Company from time to time with the Securities and Exchange Commission, including our quarterly reports on Form 10-Q. Our annual report on Form 10-K is available on the SEC's EDGAR website at www.sec.gov, and a copy may also be obtained by contacting the Company. All forward-looking statements made in this press release speak only as of the date hereof. We do not intend, and do not undertake any obligation, to update any forward-looking statements to reflect future events or circumstances after the date of such statements, except as required by law.

Additional information about InfuSystem Holdings, Inc. is available at www.infusystem.com.

CONTACT:
Joe Dorame, Joe Diaz & Robert Blum
Lytham Partners, LLC
602-889-9700

 

View original content with multimedia:http://www.prnewswire.com/news-releases/lifetime-tv-highlights-the-quality-of-life-infusystem-oncology-therapy-can-provide-300538617.html

SOURCE InfuSystem Holdings, Inc.